Abstract 171P
Background
To investigate the effect of both prostate volume and serum testosterone changes on lower urinary tract symptoms in patients with prostate cancer undergoing androgen deprivation therapy.
Methods
A total of 167 patients who received androgen deprivation therapy for prostate cancer treatment from January 2010 to August 2020 were enrolled in this retrospective study. Changes in the International Prostate Symptom Score (IPSS) in the patient groups stratified by prostate volume and the amount of testosterone reduction were assessed every 4 weeks until 12 weeks after androgen deprivation therapy initiation. Longitudinal mixed models were used to assess the adjusted effects of prostate volume and testosterone reduction on IPSS change.
Results
All mean values of IPSS-total score (IPSS-total), voiding subscore (IPSS-vs), and storage subscore (IPSS-ss) significantly decreased from baseline to week 12 in both patients with small (<33 mL) and large (≥33 mL) prostates. The mean values of IPSS-total, IPSS-vs, and IPSS-ss similarly decreased in patients with large prostate with a baseline IPSS-total of ≥13. However, in those with small prostate, IPSS-ss specifically remained unchanged, while IPSS-total and IPSS-vs significantly decreased. In addition, only in patients with small prostate (<33 mL), patients with lesser testosterone reduction (<Δ400 ng/dL) showed greater improvement in IPSS-ss by 6.3% compared with those with greater testosterone reduction (≥ Δ400 ng/dL).
Conclusions
Although androgen deprivation therapy generally improves lower urinary tract symptoms, it may not improve storage symptoms in patients with relatively small prostate and greater testosterone reduction. Our finding suggests that testosterone may influence lower urinary tract symptoms in these patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
247TiP - Addition of induction, concurrent and maintenance durvalumab to induction and concurrent chemoradiation vs induction and concurrent chemoradiation for previously untreated locoregionally advanced nasopharyngeal carcinoma: A phase II randomised-controlled trial
Presenter: Victor Lee
Session: Poster viewing 03
248P - The use of complementary medicine in Chinese pediatric patients receiving palliative care: A multi-centre study
Presenter: Chun SIng Lam
Session: Poster viewing 03
249P - Improving quality of life and symptom burden with opioids and adjuncts in lung cancer (IQSOL study)
Presenter: Naren Gokulanathan
Session: Poster viewing 03
250P - An analysis of nutritional and psychological status of patients with advanced cancer
Presenter: Shasha Wang
Session: Poster viewing 03
251P - Is QUAD SHOT palliative cyclical hypo-fractionated radiotherapy in advanced head and neck cancer the way to go? An alternative regimen in low resource countries
Presenter: Ravi Kanodia
Session: Poster viewing 03
252P - Preferred place of death among terminally ill cancer patients: A single centre observational study from India
Presenter: Suhana Sulfiker
Session: Poster viewing 03
253P - Hemostatic radiotherapy for gastric cancer: MRI as an alternative to endoscopy for post-treatment evaluation
Presenter: Osamu Tanaka
Session: Poster viewing 03
254P - Sexual function of cervical cancer survivors: A single center prospective study
Presenter: Dinesh Ravikumar
Session: Poster viewing 03
255P - Volunteers’ role to provide quality palliative care for terminal cancer
Presenter: SAPTAPARNA JANA
Session: Poster viewing 03